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1. Introduction 
Malignant glioma is the most common type of primary brain tumor and represents one of 
the most lethal cancers. In contrast to the long-standing and well-defined histopathology, 
the underlying molecular and genetic bases for gliomas are less known. (Collins, 2004; Dai & 
Holland, 2001).  
As some other human cancers, particularly central nervous tumors are highly 
heterogeneous. Primarily because of its diffuse nature, relatively little is known about the 
processes by which they develop (Hulleman & Helin, 2005). Thus, the traditional evolution 
concept of tumors arising from a single mutated cell has limitations in explaining the 
heterogeneity observed in a single tumor nest. 
Recent decades have seen only limited progress in treatment trials and basic research on 
human glioma, the most common central nervous malignancy (Huang et al., 2008). 
Unfortunately, for such gliomas, tumor recurrence after treatment is the rule due to the 
infiltrative nature of these tumors and the presence of cellular populations with ability to 
escape therapies and drive tumor recurrence and progression. At least in some cases, these 
resistant cells exhibit stem cell properties (Frosina, 2011). For these reasons the 
comprehension of the current knowledge of cancer stem cells (CSC) in relation to gliomas 
origin, growth and treatment is crucial. As the stem cells (for glioma, neuronal stem cells) 
are more susceptible to mutation, they become altered easily for their genetic composition 
and therefore act as the source of cancer/glioma cells. They are not actually a separate cell 
type and in most cases they are misinterpreted as cancer stem cells (in brain, they are glioma 
stem cells). 
2. Glioma and the concept of cancer stem cells 
For a long time it has been known that there are subpopulations of cells within solid tumors 
that contain different biological behaviors. Among these subpopulations, accumulating 
evidence supports the existence of the so-called cancer stem cells (CSCs), because these 
tumor cells possess stem cell properties, possibly being responsible for the initiation, growth 
and recurrence of tumors. Apparent similarities with non-transformed stem cells, including 
high self-renewal capacity and the ability to generate differentiated progeny of several 
cellular lineages, have led to the proposal that stem cell-like cancer cells may either originate 
from adult undifferentiated stem and progenitor cells or that these properties are being 
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expressed as an effect of the genetic alterations which drive tumorigenicity (Reya et al., 2001; 
Gilbertson, 2006; Das et al., 2008). Basically, the CSCs, which have also been described as 
tumor initiating cells or tumor propagating cells, are tumor cells that self-renew and 
propagate tumors phenotypically similar to the parental tumor (Li et al., 2009). Furthermore, 
recent studies have suggested that CSC cause tumor recurrence based on their resistance to 
radiotherapy and chemotherapy (Inoue et al, 2010).  
Although considerable controversy still surrounds the existence, behaviors and even the 
nomenclature of CSCs, there is no doubt that populations of cells with stem-like properties 
do exist inside several solid and non-solid tumors, including brain cancers. So, despite the 
fact that CSCs in solid tumors have not yet been precisely identified, the “CSC hypothesis” 
opens a new paradigm in understanding the biology of cancers. For this reason, the search 
for the tumor stem cells that may originate and perpetuate the tumor growth has been 
receiving great attention in the literature (Sanchez-Martin, 2008), but the available 
knowledge on this issue with regards to the gliomas is scant. Particularly, the exact identity 
and cell(s) of origin of the so-called glioma stem cell remains elusive (Park & Rich, 2009). 
Vescovi (2006) offered a functional definition of brain tumor stem cells, namely: brain tumor 
cells should qualify as stem cells if they show cancer-initiating ability upon orthotopic 
implantation, extensive self-renewal ability demonstrated either ex vivo or in vivo, 
karyotypic or genetic alterations, aberrant differentiation properties, capacity to generate 
non-tumorigenic end cells, and multilineage differentiation capacity. Furthermore, parallels 
between normal neurogenesis and brain tumorigenesis have been proposed (Singh et al., 
2004). It has been more recently confirmed that cancer stem cells from glioblastomas share 
some characteristics with normal neural stem cells including the expression of neural stem 
cell markers, the capacity for self-renewal and long term proliferation, the formation of 
neurospheres, and the ability to differentiate into multiple nervous system lineages 
(astrocytic, oligodendrocytic and/or neuronal differentiation) (Li et al., 2009). 
Among the so far evaluated stem cell markers, the transmembrane protein CD133 has been 
widely used to isolate putative CSC populations in several cancer types. In fact, CD133 is 
currently one of the best markers to characterize CSCs (Singh et al., 2004). In both human 
glioblastomas (GBMs) and medulloblastomas, the expression of the neural stem cell marker 
CD133 (also known as prominin 1) has been associated with both tumor initiation capacity 
and radioresistance (Pérez Castillo et al., 2008). Extensive computational comparisons with a 
compendium of published gene expression profiles revealed that the CD133 gene signature 
transcriptionally resembles human embryonic stem cells and in vitro cultured GBMs stem 
cells (GSC), and this signature successfully distinguishes GBMs from lower-grade gliomas. 
Moreover, the CD133 gene signature identifies an aggressive subtype of GBMs seen in 
younger patients with a shorter survival (Yan et al., 2011), confirming previous observations 
that Glioma stem cells are more aggressive in recurrent tumors (Huang et al., 2008). 
Nevertheless, it must be pointed out that the use of CD133 as a unique glioma stem cell 
marker is probably not sufficient to tag the whole self-renewing tumor cell reservoir 
(Clément et al., 2009). 
Holmberg et al (2011) have recently characterized human gliomas in various malignancy 
grades according to the expression of stem cell regulatory proteins. These authors have 
shown that cells in high grade glioma co-express an array of markers defining neural stem 
cells (NSCs) and that these proteins can fulfill similar functions in tumor cells as in NSCs. In 
contrast to NSCs, the glioma cells co-express neural proteins together with pluripotent stem 
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cell markers, including the transcription factors as Oct4, Sox2, Nanog and Klf4. In line with 
these findings, in high grade gliomas,  mesodermal- and endodermal-specific transcription 
factors were detected together with neural proteins, a combination of lineage markers not 
normally present in the central nervous system. These findings demonstrate a general 
deregulated expression of neural and pluripotent stem cell traits in malignant human 
gliomas. 
3. Stem cells and the origin of gliomas 
Primarily because of the diffuse nature of gliomas, relatively little is known about the 
processes by which they develop (Hulleman & Helin, 2005). The concept of stem cells 
originating gliomas is gaining increased recognition in neuro-oncology (Richj & Eyler, 2008). 
Until recently, the paradigm of a tumor-initiating stem cell was confined to hematopoietic 
malignancies where the hierarchical lineages of stem progenitor cells are well established. 
Nevertheless, the demonstration of persistent stem cells and cycling progenitors in the adult 
brain is coupled with the expansion of the cancer stem cell concept to solid tumors, leading 
to the exploration of “stemness” within gliomas. Emerging data are highly suggestive of the 
subsistence of transformed multipotential cells within a glioma, with a subfraction of cells 
exhibiting increased efficiency at tumor initiation stage. However, data in support of the 
true glioma stem cells are inconclusive to date, particularly in respect to the functional 
characterization of these cells. (Panagiotakos & Tabar, 2007). 
Thus, it may be considered that currently it is conceivable thought that malignant gliomas 
may arise from neural stem cells and appear to contain tumor stem cells. It is thought that 
normal stem cells live in protected pockets of the body called niches, where they divide 
infrequently to avoid accumulating damaging mutations. Upon injury or in response to 
normal stimuli, stem cells are mobilized to divide (Gilbertson, 2006). Hence, parallel to the 
role that normal stem cells play in organogenesis, stem cells are thought to be crucial for 
tumorigenesis. 
The normal adult neural stem cells (NSCs) arise from radial glia (RG) within the central 
nervous system (Weiner, 2008). The RG progeny includes all the main lineages of the CNS: 
neurons, astrocytes, oligodendrocytes, ependymocytes and adult neural stem cells 
(Malatesta et al. 2003). By comparing the gene expression profiles of ependymomas with 
those of cells in the normal developing nervous system, it was possible to identify the RG as 
candidate stem cells of this brain tumor (Gilbertson, 2006). Furthermore, RG cells produce 
neurons in addition to glia during central nervous system development in all vertebrates 
and are also involved in reparative process (Weiner, 2008). 
Until recently, it was thought that ependymomas originated from neuroepithelial cells, 
glioblastomas from abnormal astrocytes, and medulloblastomas from primitive cells in the 
external granular layer, but there is now evidence that all tumors can originate from a 
special type of stem cell called “radial glial cell” (RGC). It is interesting to note that in the 
human brain, most of stem cells are located in the subventricular zones (SVZ). Both supra- 
and infratentorially and when stimulated with carcinogens, cells in the SVZ become 
tumorigenic faster than those located elsewhere. In the SVZ, stem cells exist in the form of 
RGCs, which remain quiescent until they receive transformational signals. It is not clear 
whether RGCs, after receiving transformation signals, return to their initial stem cell 
configuration and then become tumorigenic or they transform to tumor progenitor cells 
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directly. In the cerebellum, depending upon the signals received, RGCs and stem cells may 
give origin to either ependymoma or medulloblastoma. 
Tumours with the highest incidence in humans— medulloblastomas and glioblastomas — 
both originate from abnormal brain stem cells. . Not surprising, both of these tumors are 
CD133-positive, containing great neuronal differentiation, which makes them prone to be 
diffuse and resistant to treatment (Castilo, 2010). 
4. Gliomas and the field cancerization concept 
It is universally accepted that tumors growth as a clonal evolution from a single cell  
(Nowell, 1976). The “field cancerization theory” was introduced more than fifty years ago 
by Slaugher et al (1953), when studying the presence of histologically abnormal tissue 
surrounding carcinomas. In a classic report on oral cancer, Slaughter called “field 
cancerization” – a process of repeated exposure of a region’s entire tissue area to 
carcinogenic insult (e.g., tobacco and alcohol), which increases the tissue’s risk for 
developing multiple independent premalignant and malignant foci. The field cancerization 
hypothesis states that multiple cells form independent tumors on one given tissue, since 
carcinogenic exposure affects multiple cells in the field (Slaughter et al., 1953), and predicts 
that second primary or synchronous tumours arise from independent genetic events (Garcia 
et al., 1999). The field cancerization theory may be explained by the concept that a given 
stem cell that acquires genetic alterations may form a “patch”, a clonal unit of altered 
daughter cells. The proliferation of these patch cells forms expanding fields which gradually 
displace the normal tissue and, by clonal divergence, ultimately leads to the development of 
one or more tumors within a contiguous field of preneoplastic cells (Garcia et al., 1999). An 
important clinical implication is that fields often remain after surgery of the primary tumor 
and may lead to new cancers, designated presently by clinicians as "a second primary 
tumor" or "local recurrence," depending on the exact site and time interval (Braakhuis et al., 
2003; Ryan, 2007). We had previously discussed how mutated clones from mutated stem 
cells may spread on tissues and that the field cancerization theory implies that the mutated 
genotype and molecular changes occur before the appearance of histopathological evidence 
of malignant cells (Garcia et al., 1999). Therefore, this "anomaly" might be due to changes 
that occur in a "premalignant" neoplastic condition that was histologically identified as 
"normal". In the clinical aspect, the field cancerization may have an etiologic role in a 
substantial number of recurrences. For example, a surgical resection margin that includes a 
genetically altered field can explain the occurrence of scar recurrence. This explanation 
suggests that molecular profiling of surgical margins will help reduce scar recurrences. 
Since multiple independent patches of cancer fields may be present in the same organ 
exposed to the same insults, clean molecular margins may not necessarily prevent 
recurrences in the residual organ (Dakubo et al., 2007). Similarly to gliomas, tumor 
recurrence is a major clinical concern for patients with urothelial carcinoma of the urinary 
bladder. Traditional morphological analysis is of limited utility for identifying cases in 
which recurrence will occur. However, recent studies have suggested that urothelial 
carcinogenesis occurs as a ‘field effect’ that can involve any number of sites in the bladder 
mucosa. Accumulating evidence supports the notion that resident urothelial stem cells in 
the affected field are transformed into cancer stem cells by acquiring genetic alterations that 
lead to tumor formation through clonal expansion (Cheng et al., 2009). 
www.intechopen.com
 The Role of Stem Cells in the Glioma Growth 
 
193 
The available information in regards to the existence of a field phenomenon in gliomas is 
scant. In malignant gliomas, the high recurrence rates, the characteristically heterogeneous 
features and frequent diffuse spread within the brain have raised the question of whether 
malignant gliomas arise monoclonally from a single precursor cell or polyclonally from 
multiple transformed cells forming confluent clones (Inoue et al., 2008). To address this 
issue, Kattar et al (1997) have evaluated the clonality of low-grade and malignant gliomas by 
using polymerase chain reaction (PCR)-based assay for nonrandom X chromosome 
inactivation using surgical and autopsy material. The same pattern of nonrandom X 
chromosome inactivation was present in all areas of fifteen of 19 tumors, which were 
considered as monoclonal, suggesting that low-grade and malignant gliomas are, at least, 
usually monoclonal tumors, and extensively infiltrating tumors must result from migration 
of tumor cells. 
Gliomatosis cerebri may shed some light in this issue. It is a rare condition in which the brain 
is infiltrated by an exceptionally diffusely growing of malignant glial cell population 
involving at least 2 lobes, though often more extensive, sometimes even affecting 
infratentorial regions. Kross et al (2002) have evaluated the existence of field cancerization in 
this affection, since gliomatosis cerebri may initiate as an oligoclonal process or result from 
collision of different gliomas. It was hypothesized that the presence of an identical set of 
genetic aberrations throughout the lesion would point to monoclonality of the process. In 
contrast, the finding of non-identical genetic changes in widely separated regions within the 
neoplasm would support the concept of collision of different mutated clones. For such, the 
authors used one autopsy case of gliomatosis cerebri, from which tissue samples were 
randomly taken from 24 locations throughout the brain and used for genetic investigation. 
With this aim, genome-wide screening for chromosomal aberrations was accomplished by 
comparative genomic hybridization (CGH). The authors found a wide distribution of 
particular sets of genetic aberrations, supporting the concept of monoclonal tumor 
proliferation (Kross et al., 2002). Nevertheless, it has been observed and well documented in 
one clinical case that on the long term, after initial treatment for gliomatosis cerebri, one 
glioblastoma multiforme has developed, and in a location separate from the initial lesion, 
suggesting that different clonal origin may had occurred (Inoue et al., 2008). More recently, 
Chen et al (2010) showed that the capacities for self-renewal and tumour initiation in GBM 
need not be restricted to a uniform population of stemlike cells.  
5. The contribution of studies in animal models: Unifying the cancer stem 
cells and field cancerization concepts 
Many genetic alterations have been identified in human gliomas, however, establishing 
unequivocal correlation between these genetic alterations and gliomagenesis requires 
accurate animal models for these cancers (Dai & Holland, 2001). Indeed, it is useful and 
necessary to have animal models for CNS tumors studies allowing to be carried out in 
different stages of  tumor growth, especially in  early stages, rare to be detected and 
observed in clinical practice (Bulnes-Sesma, 2006). 
Experimental models of gliomagenesis most commonly used alkylating agents such as N-
ethyl N-nitrosourea (ENU), which has been considered as a suitable model to study 
malignant changes. These changes were reported to appear firstly as early neoplastic 
proliferation (ENP) center, which continues in following stages subsequently progressing to 
‘‘microtumors’’ until a tumor in itself. (Koestner et al., 1971; Naito et al., 1984).  
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By using the experimental model of gliomagenesis induced by the N-ethyl N-nitrosourea, 
we were able to detect putative tumor stem cells in early oncogenesis, yielding to analyze a 
field cancerization process and observe a close morphological relationship between 
metallothionein (MT) positive cells and blood vessels. With this aim, we have developed an 
experimental model to track putative mutated stem cells, using the ENU experimental 
model and metallothioneins (MT) immunostaining. MTs are metal binding proteins that 
take part in the homeostasis of the ions of the metals which are necessary for the proper 
metabolism of the organism (zinc, copper), disintoxication of metals and protect the tissues 
from the effects of free radicals, radiation and from mutagens (Thirumoorthy et al., 2007). 
MT expression is present in a significant portion of especially malignant brain tumors. In 
astrocytic tumors an acquired enhanced ability to produce MT has been observed as the 
malignant potential of a tumor increases (Hiura et al., 1998), and MT might be involved in 
poor response to antineoplastic drugs (Maier et al., 1997). In the murine colonic mucosa, the 
crypt restricted immunopositivity for MT has been shown to be reliable marker of stem cell 
mutation that may be induced early after mutagen treatment and that can be assayed in 
paraffin-fixed tissue sections (Cook et al., 2000). We have observed that 30 days after the 
treatment of rats with ENU, the main location of the MT positive cells have striking 
similarity to that of the RG cells and that the frequency of these cells (a) is strongly 
correlated with the increased appearing of ENP centers and new blood vessels, (b) is 
augmented at higher levels in long-term observation, i.e., 180 days after the carcinogen 
administration, (c) is related to a high staining intensity in both nucleus and cytoplasm, and 
(d) is very similar to the pattern of immunostaining that was observed in the nervous tissue 
surrounding gliomas, which were originated at an average of 321 days after the ENU 
administration (Fernandes-da-Silva et al., 2009). The mechanisms and reasons why MT is 
expressed in the preneoplastic and neoplastic lesions remain to be fully elucidated. It has 
been hypothesized that mutation-induced MT overexpression may interfere with the 
function of zinc finger DNA binding transcription factors (Zeng et al., 1991), which have 
been implicated in transcriptional control of various genes, including TP53, involved in cell 
proliferation and apoptosis. These MT-mediated effects on gene transcription are thought to 
confer a selective growth or survival advantage (or both) on the mutated cells (Bruewer, 
2002). 
6. Glioma, stem cells niche and angiogenesis 
Recently in a review article, Gilbertson & Rich JN (2007) address a number of key questions 
which remain to be answered: do all cancer stem cells require the support of aberrant 
niches? Are cancer stem cell niches the primary drivers of tumor development, or are they 
recruited by pre-formed cancer stem cells? How do cancer stem cells and their niches 
subvert the tight regulatory conditions that characterize normal stem cell niches?  
The stem cells of glioblastoma seem to be dependent on signals from aberrant vascular 
niches that mimic the normal neural stem cell niche (Gilbertson & Rich, 2007). Stem cells of 
various tissues are tightly regulated by the immediate microenvironment or stem cell niche 
(Moore & Lemischka, 2006), which is provided by capillaries in specific locations (Riquelme 
et al., 2008). This organization places the stem cells in close proximity to endothelial and 
other vascular cells, facilitating cross-talking among these cell types and affecting stem cell 
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fate choices (Gilbertson, 2006). It is well-known that stem cells and their microenvironments 
may influence each other (Scadden, 2006). In fact, Cues within the niche, from cell–cell 
interactions to diffusible factors, are spatially and temporally coordinated to regulate 
proliferation and neurogenesis, ultimately (Riquelme et al., 2008). 
In ENU treated rats, we have observed the existence of a close morphological relationship 
between MT positive cells and blood vessels. What is the relationship between them? It is 
known that MT is involved in the regulation of the functions of endothelial cells as well as in 
their protection against cytotoxic agents (Kaji et al., 1993). MT knock-out (MT-KO) mice 
presented dramatically decreased IL-6-induced angiogenesis caused by cortical freeze 
injury, suggesting that the MT have major regulatory functions in the angiogenesis process 
(Penkowa et al., 2000). In fact, human CD133+ Glioma CSCs are capable of producing 
vascular endothelial growth factor (VEGF) and thus may play an important role in glioma 
angiogenesis (Yao et al.,2008). 
7. The concept of stemness, modulation of csc and glioma treatment 
Understanding the characteristics and function of CSCs has shed light on their roles in glioma 
progression, including the implications for prognosis and treatment resistance. The original 
use of the term stemness was derived from a number of articles aimed to look for genes that 
could be expressed in general stem cell populations. The stemness hypothesis states that all stem 
cells use common mechanisms to regulate self-renewal and multi-lineage potential. This 
hypothesis has been debated and so far no conclusive evidence for a set of genes expressed in 
all stem cells. Certainly, identifying genes regulating stem cell properties will greatly improve 
our understanding of the molecular mechanisms regulating stem cell functions, our ability to 
manipulate stem cell fate, and the roles of stem cells in cancer (Koeva et al., 2011). 
Interestingly, overexpression of the transcription factor NANOG in gliomas and its close 
relationship with the undifferentiated state of glioma cells in vivo and in vitro indicated that 
NANOG may contribute to the existence of brains CSCs and may be related to tumorigenesis 
of the cerebrum by maintaining the undifferentiated state of glioma cells (Niu et al., 2011). 
The new concept stemness is closely related to the observation that there are tissue 
environment factors that are able to influence or modulate CSCs. The main one is hypoxia, 
which activates the Hypoxia Induced Factor alpha number 1 (HIFα-1) alpha to enhance the 
self-renewal activity of CD133-positive cells and to inhibit their differentiation (Soeda et al., 
2009). This and other signaling systems drive the transformation of normal stem cells, and 
perhaps of the bulk of tumor cells to cancer stem cells or to maintain the CSC phenotype 
(Katoh, 2011). For instance, the oxygen level of 7% has been observed to enhance the stem 
cell–like phenotype of CD133+ in GBM cells (McCord et al., 2009). Furthermore, it has been 
observed that human glioblastoma cells from tumor biopsies, which were engrafted 
intracerebrally into nude rats, that CD133 negative glioma cells were tumorgenic in nude 
rats, and that CD133 positive cells can be obtained from these tumors. Upon the passing of 
the cell tumors in vivo, CD133 expression is upregulated, coinciding with the onset of 
angiogenesis and a shorter patient survival (Wang et al., 2008). Furthermore, the bone 
morphogenic protein BMP4 effectively reduces proliferation of CD133 positive cells in vitro 
and the tumor growth in vivo. BMP4 may act as a key inhibitory regulator of cancer 
initiation and therefore may be used in combined stem cell-based therapy as a non-cytotoxic 
therapeutic agent (Altaner, 2008). 
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If one accepts that there is a subpopulation of cancer cells with stem cell properties, which is 
responsible for tumor maintenance and progression, and may contribute to the resistance to 
anticancer treatments, it is very reasonable to deduce that compounds that target cancer 
stem-like cells could be effective to impair or even to destroy a neoplasm and nas important 
therapeutic implications. Various compounds have been investigated as putative influencers 
of stemness and malignancies in glioma stem-like cells, leading the proposal that stem cell 
regulatory factors may provide significant targets for therapeutic strategies (Holmberg et al., 
2011). Ongoing work aims the identification of unique pathways governing self-renewal of 
these putative stem cells and their validation as ultimate therapeutic targets (Panagiotakos 
& Tabar, 2007). Additionally, it is possible to conceive that epigenetic-based drugs that 
modulate gene expression in CSC possibly constitute a promising alternative resource for 
target therapy in the treatment of these, thus far, incurable malignancy. 
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